NEW YORK (GenomeWeb News) – Wyeth has extended an ongoing microarray supply agreement with Affymetrix for three more years, Affymetrix said today.
 
Under the terms of the agreement, originally signed in 1994, Wyeth will continue to use Affy’s GeneChip technology to identify new drug targets and to study genetic markers linked to therapeutic response.
 
Affy said Wyeth also uses its GeneChip products for disease classification and in predicting clinical progression.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.